Abstract Background Stroke thombolysis has been a proven effective treatment for acute stroke since 1995. Since then Alteplase the standard thrombolytic agent used in hyperacute patient, dose being decided by body weight (0.9mg/kg). 10% of is given as bolus, and remaining 90% an infusion. As based, more than one vial can be required. Tenecteplase recent agent, 2017 large multi-centre randomised...

P a t i e n t s 840 patients (median age 58 y, 82% men) with symptoms of MI for ≤ 6 hours. Exclusion criteria were known bleeding disorders or contraindication to fibrinolysis, severe renal or hepatic insufficiency, aortofemoral bypass or hampered femoral artery access, cardiogenic shock, history of coronary artery bypass graft surgery, current oral anticoagulant treatment, or expected duration...

A suicide bomb blast in 2013 at a distant city of Pakistan killed 84 and wounded more than 150 people. Some patients were transferred to our tertiary care hospital because of extreme load on medical services there. This patient arrived at the Aga Khan Hospital, 2 days after the bomb blast injury and underwent an orthopedic procedure. Next day, he developed sudden tachypnea, desaturation, and ci...

Cerebral venous sinus thrombosis (CVST) can have devastating results, with mortality reported in 44% of cases. No randomized trials exist in order to define what qualifies as failure of conservative therapy, and there is no specific intervention to date which is considered safe and effective. Case series suggest that thrombolysis infusion is safer than thrombectomy, but methods of administratio...

OBJECTIVE To assess the usefulness of heparin, alteplase, and streptokinase in removing blood stains. DESIGN Randomised controlled trial. SETTING Hospital laundry. INTERVENTIONS Blood stains were allocated to treatment with alteplase, streptokinase, heparin, a commercial enzymatic stain remover, or no treatment at all after three or seven hours and then washed in hot or cold water two hou...

Phatmecokinetics and fibrin specificity of alteptase (recombinant thane-type plasminogen activator) were determined in IO patients with made, myorard td infarction undergoing as aorelers •^t alzsion regimen during the alteplaselaniatreplase potency study (TAPS). Fifteen milligrams of alteplase was a dministered as an intravenous halos injection, fdNowed by infisims of 50 mg over 30 min and 35 m...

Dr. Evelyn Walter IPF Institute for Pharmaeconomic Research Wolfengasse 4/7 1010 Vienna, Austria Tel +43-1-5132007-13 Fax +43-1-5132007-15 Email: [email protected] Web: www.ipf-ac.at Objectives Worldwide, stroke is the third most common cause of death in developed countries with declining death rates. In Austria the incidence rate of stroke is 2.1 – 2.3 per thousand annually. Cerebrolysin prev...

Central venous access device (CVAD) dysfunction, with loss of patency because of thrombotic occlusion, has been reported to be the most common complication in central lines, even more common than catheter-related infection (Moureau, Poole, Murdock, Gray, & Semba, 2002). Occlusion of CVADs can cause life-threatening treatment delays, patient discomfort, infection, and the need for catheter remov...

lization of intravenous thrombolysis with alteplase was very low in Taiwanese patients with acute ischemic stroke(1). One of the reasons is the strict reimbursement guideline made by the Bureau of National Health Insurance (NHI) in 2004(2). In this issue of the Acta Neurologica Taiwanica, Yu-Hsiang Su and co-authors(3) retrospectively evaluated outcomes of their thrombolysed stroke patients who...